Printer Friendly

NORTH AMERICAN BIOLOGICALS, INC. AWARDED $45 MILLION EUROPEAN CONTRACT: PLASMA ORDER IS LARGEST IN NABI'S HISTORY

NORTH AMERICAN BIOLOGICALS, INC. AWARDED $45 MILLION EUROPEAN CONTRACT:
 PLASMA ORDER IS LARGEST IN NABI'S HISTORY
 FRANKFURT, Germany, Sept. 17 /PRNewswire/ -- North American Biologicals, Inc. ("NABI") (NASDAQ: NBIO) today announced it has been awarded a multi-year plasma supply contract, valued at a total of at least $45 million for the first two years combined, from a multinational biologicals company based in Europe. The contract, which begins in 1993 and is mostly for source plasma, replaces a current agreement that provided approximately $10 million in revenue for 1992. The current contract expires at the end of this year. All of NABI's international supply agreements are denominated in U.S. currency.
 "The expansion and renewal of this contract, which is NABI's largest contract to date, depicts the growth opportunities available to NABI, due to an increase in European demand and the direct access gained to this marketplace as a result of our March 31 acquisition," said David Gury, NABI's Chairman, President and Chief Executive Officer. "NABI is actively pursuing these opportunities, while simultaneously addressing the challenges of plasma shortage facing the industry."
 In response to the increase in worldwide demand for plasma products, NABI is aggressively implementing a comprehensive plan to increase plasma production by emphasizing new donor recruitment programs and reducing operating costs at its Biomedical Centers. The plan includes strategic acquisitions of new Biomedical Centers, renovation of existing Centers, and continued automation of its collection facilities within the Centers. Gury also added that he anticipates, over time, these programs will increase plasma production and enhance profitability through operating efficiencies.
 North American Biologicals, Inc. is the world's largest independent provider of human blood plasma elements to the health care industry. The company collects, processes, tests and distributes human-blood- related products, manufactures and markets plasma/sera-based diagnostic products and markets clinical diagnostic testing services.
 -0- 9/17/92
 /CONTACT: David J. Gury, chairman, president and CEO, or Alfred J. Fernandez, VP finance, North American Biologicals, 305-625-5303, or Lori Martin, account executive, Feinstein Partners, 617-577-8110, for NABI/
 (NBIO) CO: North American Biologicals, Inc. ST: Florida IN: MTC SU: CON


CN -- NE006 -- 0688 09/17/92 13:11 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 17, 1992
Words:355
Previous Article:USAIR CHAIRMAN SETH E. SCHOFIELD ISSUES STATEMENT
Next Article:WEEKEND BUSES ON SEPTA ROUTE 100, VILLANOVA-NORRISTOWN
Topics:


Related Articles
NORTH AMERICAN BIOLOGICALS, INC. ANNOUNCES THIRD QUARTER AND NINE MONTHS 1992 RESULTS
NORTH AMERICAN BIOLOGICALS TO ACQUIRE MAJOR PLASMA COMPANY
NORTH AMERICAN BIOLOGICALS, INC. REPORTS RECORD REVENUES AND PROFITS FOR 1993
NORTH AMERICAN BIOLOGICALS, INC. FILES REGISTRATION STATEMENT WITH SEC FOR PUBLIC OFFERING
NORTH AMERICAN BIOLOGICALS, INC. REPORTS RECORD RESULTS FOR SECOND QUARTER 1995
MICHIGAN DEPARTMENT OF PUBLIC HEALTH SIGNS MANUFACTURING AGREEMENT WITH NORTH AMERICAN BIOLOGICALS, INCORPORATED
NORTH AMERICAN BIOLOGICALS, INC. REPORTS RECORD RESULTS FOR SECOND QUARTER 1995
Ratings on NABI Lowered & Placed on S&P Watch Developing
Nabi(R) and BioProducts Laboratory Sign $30 Million Two Year Plasma Supply Agreement
Nabi(R) Appoints Bruce Farley as Senior Vice President, Manufacturing Operations.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters